High-Profile Clinical Trial Suspensions Caused by Audit Findings

Introduction: When Audit Findings Halt Clinical Development

Regulatory audits play a crucial role in ensuring that clinical trials comply with ICH GCP and national legislation. In some cases, deficiencies are so significant that regulators suspend or place studies on clinical hold until issues are resolved. Such high-profile suspensions attract attention because they delay product development, increase costs, and can damage the sponsor’s reputation.

Agencies such as the FDA, EMA, and MHRA typically impose suspensions when findings pose risks to patient safety, compromise data integrity, or reveal systemic quality management failures. Reviewing these cases highlights how inadequate CAPA, superficial RCA, and weak sponsor oversight can escalate findings into trial-halting events.

Regulatory Expectations in Preventing Suspensions

Authorities expect sponsors and CROs to demonstrate:

• Robust safety monitoring systems with timely SAE and SUSAR reporting.
• Inspection-ready TMF with complete documentation of oversight and approvals.
• Effective oversight of CROs, vendors, and subcontractors.
• Structured CAPA systems with evidence-based preventive measures.
• Accountability at senior management level for compliance and trial governance.

The ISRCTN Registry reflects the importance of transparency and oversight in clinical trials, aligning with global regulatory priorities.

Case Study 1: FDA Suspension of a Phase III Oncology Trial

In a Phase III oncology study, the FDA issued a clinical hold after identifying incomplete SAE follow-up and missing informed consent documentation. The sponsor’s CAPA response was deemed inadequate, focusing on staff retraining without implementing systemic improvements. Recruitment was halted for nine months, delaying submission of a New Drug Application (NDA).

Case Study 2: EMA Suspension of a Rare Disease Trial

EMA inspectors suspended a Phase II rare metabolic disorder trial after repeated TMF deficiencies were discovered, including missing ethics committee approvals and delegation logs. Despite prior audit commitments, the same findings recurred due to weak sponsor oversight of CRO activities. The suspension lasted nearly a year, resulting in significant reputational damage.

Case Study 3: MHRA Suspension for Data Integrity Failures

In a UK-based Phase I trial, MHRA inspectors identified unauthorized changes to eCRF data without audit trails. The sponsor attributed this to “technical errors,” but RCA revealed no validation of electronic systems. The MHRA suspended the trial until validated systems and oversight mechanisms were implemented.

Root Causes of Trial Suspensions

Analysis of suspension cases reveals root causes such as:

• Superficial RCA attributing issues to “human error” without systemic fixes.
• Poor sponsor oversight of CROs, vendors, and subcontractors.
• Absence of validated systems for data management and TMF maintenance.
• Failure to allocate sufficient resources for compliance and documentation.
• Weak CAPA systems with no evidence of effectiveness checks.